Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Xeomin
Therapeutic Area : Urology
Study Phase : Undisclosed
Sponsor : Blueclinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xeomin is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Urinary Bladder, Overactive.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Xeomin
Therapeutic Area : Urology
Highest Development Status : Undisclosed
Sponsor : Blueclinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Merz Pharma
Deal Size : $19.0 million
Deal Type : Partnership
Merz Strengthens Partnership With Start-up Vensica and Invests up to $3 million
Details : This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN®) for the innovative ultrasound-assisted delivery catheter of Vensica.
Product Name : Xeomin
Product Type : Protein
Upfront Cash : Undisclosed
February 07, 2022
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Merz Pharma
Deal Size : $19.0 million
Deal Type : Partnership
Reset All
